InnoCan PharmaINNPF -10.53%56 EBITDA Margin % is -12.48% as of Mar. 2026. GuruFocus rates INNPF with a GF Score™ of 56/100 and a GF Value™ of $10.03 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 1,951 Consumer Packaged Goods companies, InnoCan Pharma ranks worse than 84.73% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. InnoCan Pharma's EBITDA for the
three
months ended in Mar. 2026 was $-0.81 Mil. InnoCan Pharma's Revenue for the
three
months ended in Mar. 2026 was $6.47 Mil. Therefore, InnoCan Pharma's EBITDA margin for the quarter that ended in Mar. 2026 was -12.48%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
InnoCan Pharma EBITDA Margin % Related Terms
InnoCan Pharma EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for InnoCan Pharma's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Household & Personal Products subindustry, InnoCan Pharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InnoCan Pharma EBITDA Margin % vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, InnoCan Pharma's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where InnoCan Pharma's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InnoCan Pharma (INNPF) has a EBITDA Margin % of -12.48% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on InnoCan Pharma and its competitors. According to the industry distribution chart, InnoCan Pharma ranks #1653 out of 1951 companies in the Consumer Packaged Goods industry, placing it in the top 84.7%.
Is InnoCan Pharma's EBITDA Margin % too high?
InnoCan Pharma's current EBITDA Margin % is -12.48%. Based on the distribution chart, InnoCan Pharma ranks #1653 out of 1951 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, InnoCan Pharma has a GF Score™ of 56/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InnoCan Pharma's EBITDA Margin % compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, InnoCan Pharma ranks #1653 out of 1951 companies for EBITDA Margin %. This places InnoCan Pharma in the lower half of its industry. The industry median EBITDA Margin % is 8.97. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Consumer Packaged Goods company?
The median EBITDA Margin % among Consumer Packaged Goods companies is 8.97, based on 1,951 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on InnoCan Pharma and its competitors. For the Consumer Packaged Goods industry, the median EBITDA Margin % is 8.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InnoCan Pharma's current EBITDA Margin % is -12.48%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InnoCan Pharma stock overvalued right now?
Based on GuruFocus' analysis, InnoCan Pharma (INNPF) is currently considered Possible Value Trap. The stock's GF Value™ is $10.03, compared to a current price of $1.70 — trading 83.1% below its estimated fair value. The current EBITDA Margin % is -12.48%. InnoCan Pharma's overall GF Score™ is 56/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For InnoCan Pharma (INNPF), the current EBITDA Margin % is -12.48% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InnoCan Pharma (INNPF) Overvalued in 2026?
Based on GuruFocus' analysis, InnoCan Pharma stock appears to be undervalued.
The current stock price of $1.70 is trading 83.1% below its estimated GF Value™ of $10.03.
GuruFocus considers InnoCan Pharma to be Possible Value Trap.
Key valuation signals for INNPF:
EBITDA Margin %: -12.48%
GF Value™: $10.03 vs. price of $1.70 (83.1% below fair value)
No single metric tells the full story. See the INNPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InnoCan Pharma Corp develops consumer wellness and pharmaceutical products. It has developed a preclinical-stage Cannabidiol-loaded Liposome injection Platform (CBD-LPT) for non-opioid pain management, and is involved in developing and marketing various self-care and CBD beauty products. Additionally, the Group offers cosmetic products such as anti-aging beauty sleeping masks, anti-puffiness eye serum, anti-aging facial serum, hair cream, etc., which are sold mainly through online marketplaces. Its operating segments are: Online sales and Other operations. The majority of its revenue is generated from the Online sales segment, which engages in the development, manufacture, and marketing of cosmetic products. Geographically, the Group generates maximum revenue from the United States.
56GF Score
Get the complete analysis for INNPF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INNPF has been successfully added to your 
